MedTrace Logo

Clinical Investigation of Visual Function After Bilateral Implantation of Two Presbyopia-Correcting Trifocal Intraocular Lenses (IOL)

NCT02691741 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 215

Last updated 2019-09-27

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to clinically evaluate the visual performance of two commercially available presbyopia-correcting Trifocal IOLs.

Conditions

  • Cataracts

Interventions

DEVICE

AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL

Trifocal IOL(near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient

DEVICE

AT LISA® tri IOL

Trifocal IOL(near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Sr. Clinical Manager, GCRA · Alcon, a Novartis Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-29
Primary Completion
2017-07-17
Completion
2017-07-17
FDA Device
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02691741 on ClinicalTrials.gov